scispace - formally typeset
Book ChapterDOI

Mechanisms of multidrug resistance in cancer.

Reads0
Chats0
TLDR
Identifying genes and mechanisms critical to the development of MDR in vivo and establishing a reliable method for analyzing clinical samples could help to predict theDevelopment of resistance and lead to treatments designed to circumvent it.
Abstract
The development of multidrug resistance (MDR) to chemotherapy remains a major challenge in the treatment of cancer. Resistance exists against every effective anticancer drug and can develop by numerous mechanisms including decreased drug uptake, increased drug efflux, activation of detoxifying systems, activation of DNA repair mechanisms, evasion of drug-induced apoptosis, etc. In the first part of this chapter, we briefly summarize the current knowledge on individual cellular mechanisms responsible for MDR, with a special emphasis on ATP-binding cassette transporters, perhaps the main theme of this textbook. Although extensive work has been done to characterize MDR mechanisms in vitro, the translation of this knowledge to the clinic has not been crowned with success. Therefore, identifying genes and mechanisms critical to the development of MDR in vivo and establishing a reliable method for analyzing clinical samples could help to predict the development of resistance and lead to treatments designed to circumvent it. Our thoughts about translational research needed to achieve significant progress in the understanding of this complex phenomenon are therefore discussed in a third section. The pleotropic response of cancer cells to chemotherapy is summarized in a concluding diagram.

read more

Citations
More filters
Patent

Treating cancer with drug combinations

TL;DR: In the field of cancer therapy, the authors found that over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets, and used them in cancer therapy.
Journal ArticleDOI

Exploring novel fluorine-rich fuberidazole derivatives as hypoxic cancer inhibitors: Design, synthesis, pharmacokinetics, molecular docking, and DFT evaluations

Muhammad Babar Taj, +1 more
- 06 Jan 2022 - 
TL;DR: This study presents a novel class of fuberidazole derivatives with selectivity toward hypoxic cancer cells, prepared and characterized as potential new anticancer bioreductive prodrugs and showed good cytotoxic properties.
Journal ArticleDOI

Inhibition of Chemoresistance in Primary Tumor Cells by Camellia sinensis non fermentatum Extract Noviphenone (NPE

TL;DR: Although NPE® did not alter pump gene expression, it was able to reduce pump activity, thus allowing the chemotherapeutic agent to stay inside the cells to exert its full anticancer activity and improve the overall survival of cancer patients.
Journal ArticleDOI

ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell Lines

TL;DR: In this article , the authors investigated the susceptibility of HS-173 to efflux mediated by the multidrug efflux transporters ABCB1 and ABCG2, which are two of the most well-known ATP-binding cassette (ABC)-transporters associated with the development of cancer multidisrug resistance (MDR).
References
More filters
Journal ArticleDOI

ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform

TL;DR: ONCOMINE is presented, a cancer microarray database and web-based data-mining platform aimed at facilitating discovery from genome-wide expression analyses and novel biomarkers and therapeutic targets are discovered.
Journal ArticleDOI

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.

TL;DR: Observations on the molecular basis of pleiotropic drug resistance are interpreted in terms of a model wherein certain surface glycoproteins control drug permeation by modulating the properties of hydrophobic membrane regions.
Journal ArticleDOI

Targeting multidrug resistance in cancer

TL;DR: Various approaches to combating multidrug-resistant cancer are described, including the development of drugs that engage, evade or exploit efflux by ABC transporters.
Journal ArticleDOI

Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line

TL;DR: Reversion to drug sensitivity was associated with loss of gene amplification and a marked decrease in mRNA expression, and the mRNA encodes a member of the ATP-binding cassette transmembrane transporter superfamily.
Journal ArticleDOI

A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity

TL;DR: It is hypothesized that the presence of a rare codon, marked by the synonymous polymorphism, affects the timing of cotranslational folding and insertion of P-gp into the membrane, thereby altering the structure of substrate and inhibitor interaction sites.
Related Papers (5)